Abstract
The altered glucose metabolism in cancer cells, known as the Warburg effect, is a new area of research of anticancer agents [1]. To date, many compounds have been identified that address the glucose metabolism. However, many of them failed at the early stages of clinical trials, demonstrating systemic toxicity [2, 3]. The glycolysis inhibitor iodoacetate (IA) has a good antitumor effect, but, like other glycolysis inhibitors, it has an unsafe profile. Liposomes (LS) are a good element to provide the required targeted delivery and reduce the systemic toxicity of drugs. The aim of our study was to identify the effect of iodoacetate encapsulation in liposomes made on its antitumor properties and assess the systemic toxicity thereof.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
